FDA Approves Ilumya for Adults With Active Psoriatic Arthritis

The FDA has approved Ilumya for adults with active psoriatic arthritis, according to PharmExec. The publication reported that the approval adds a psoriatic arthritis indication for tildrakizumab, Sun Pharma’s IL-23 inhibitor.

The FDA decision is an indication update for Ilumya in an adult population with active psoriatic arthritis. PharmExec identified Ilumya as tildrakizumab and described the product as an IL-23 inhibitor from Sun Pharma.

FDA approval reported for active psoriatic arthritis

PharmExec reported that the FDA approval applies to adults with active psoriatic arthritis. The report centers on Ilumya’s newly approved use in this patient population and identifies the medicine by both its brand and nonproprietary names.

For medical and pharmaceutical sales professionals, the reported event provides a clear product-and-indication update: Ilumya, or tildrakizumab, has received FDA approval for adults with active psoriatic arthritis. Communications about the event should distinguish the reported indication from broader product discussions.

Reported product details

According to PharmExec, Ilumya is Sun Pharma’s IL-23 inhibitor. The publication’s announcement linked the FDA action to the active psoriatic arthritis indication and the adult population specified in the approval report.

PharmExec also noted that the announcement cited no phase 3 efficacy figures. That absence is relevant when reviewing the reported approval update: the available evidence describes the FDA action, the product, its IL-23 inhibitor classification, and the approved adult active psoriatic arthritis population, without phase 3 efficacy figures.

Key points from PharmExec

• The FDA approved Ilumya for adults with active psoriatic arthritis.
• Ilumya is tildrakizumab.
• Sun Pharma’s product is described as an IL-23 inhibitor.
• The announcement cited no phase 3 efficacy figures.